Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




COX-2 Inhibitors Slow Bone Growth and Impede Healing

By Biotechdaily staff writers
Posted on 04 Dec 2002
Researchers working with a rabbit model have found that selective COX-2 inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex) interfere with the healing process after a bone fracture or cementless joint implant surgery. More...
These findings were published in the November 2002 issue of the Journal of Orthopedic Research.

"It is very common. You break a bone and go to the ER. The doctor sets it in a splint and prescribes one of these anti-inflammatory drugs (including COX-2 inhibitors) for pain,” said first author Dr. Stuart Goodman, MD, professor of orthopedic surgery at the Stanford School of Medicine (Stanford, CA, USA). "We now know that could actually delay healing.”

The investigators implanted a titanium device called a harvest chamber into the tibia bone of eight New Zealand white rabbits. The device has a removable, hollow inner core that allows periodic removal of the tissue growing inside. The growth of new bone into the chamber simulates healing of a fracture or joint implant. The rabbits were given oral treatments of naproxen (a nonspecific COX inhibitor) or rofecoxib separated by four weeks without treatment. After each treatment, the harvest chamber's core was removed and the tissue growing inside extracted and examined under the microscope using special stains, including monoclonal antibodies.

Since the harvest chamber allows new tissue to be extracted multiple times as it grows back, the rabbits served as their own control groups (after consuming plain water). The researchers found that while the tissue in the control group contained 24.8% and 29.9% new bone growth, the tissue harvested after the rabbits consumed naproxen and rofecoxib contained significantly less: 15.9% and 18.5%, respectively. As the difference in new bone growth associated with the two drugs was statistically insignificant, the COX-2 inhibitor impeded new bone growth as much as the nonspecific NSAID.

Dr. Goodman said this study "has great applicability to humans, because the healing process is virtually the same” for rabbit and human bones.



Related Links:
Stanford University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.